HIV-1 Drug Resistance and Associated Factors Among Adults Failing First-Line Highly Active Antiretroviral Therapy in Ho Chi Minh City, Vietnam

REFERENCES

• Vietnam Authority of HIV/AIDS Control. Vietnam HIV/AIDS Estimates and Projections, 2007–2012. Hanoi: Ministry of Health; 2009.
   Google Scholar
• Pham QD, Wilson DP, Zhang L. A review of the extent of HIV drug resistance in Vietnam. J AIDS Clin Res. 2012;S5:001.
   Google Scholar
• Bontell I, Cuongdo D, Agneskog E, Diwan V, Larsson M, Sonnerborg A. Transmitted drug resistance and phylo-genetic analysis of HIV CRF01_AE in Northern Vietnam. Infect Genet EvoL 2012;12(2):448–452.
   PubMed Web of Science ®Google Scholar
• Dean J, Ta Thi TH, Dunford L, et al. Prevalence of HIV type 1 antiretroviral drug resistance mutations in Viet-nam: a multicenter study. AIDS Res Hum Retroviruses. 2011;27(7):797–801.
   PubMed Web of Science ®Google Scholar
• Ishizaki A, Cuong NH, Thuc PV, et al. Profile of HIV type 1 infection and genotypic resistance mutations to antiretro-viral drugs in treatment-naive HIV type 1-infected individu-als in Hai Phong, Viet Nam. AIDS Res Hum Retroviruses. 2009;25(2)1 75–182.
   Web of Science ®Google Scholar
• Wittkop L, Gunthard HF, de Wolf F, et al. Effect of trans-mitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multico-hort study. Lancet Infect Dis. 201111(5):363–371.
   Google Scholar
• Vietnamese Ministry of Health. The National Guidelines for Diagnosis and Treatment of HIV/AIDS. Hanoi: Ministry of Health; 2009.
   Google Scholar
• Tran VT, Ishizaki A, Nguyen CH, et al. No increase of drug-resistant HIV type 1 prevalence among drug-naive individuals in northern Vietnam. AIDS Res Hum Retrovi-ruses. 2012;28(10)1349–1351.
   Web of Science ®Google Scholar
• Ayouba A, Lien TTX, Nouhin J, et al. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from burkina Faso, Cote d'Ivoire, sen-egal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum Retroviruses. 2009;25(11):1193–1196.
   PubMed Web of Science ®Google Scholar
• Hien TN, Nguyen BD, Shrivastava R, et al. HIV drug resis-tance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam. Antivir Ther 2008;13\(suppl 2):115–121.
   Google Scholar
• Duc NB, Hien BT, Wagar N, et al. Surveillance of transmit-ted HIV drug resistance using matched plasma and dried blood spot specimens from voluntary counseling and test-ing sites in Ho Chi Minh City, Vietnam, 2007–2008. Clin Infect Dis. 2012;54\(suppl 4):5343–5347.
   Google Scholar
• Vietnamese Ministry of Health. The National Guidelines for Diagnosis and Treatment of HIV/AIDS. Hanoi: Author; 2005.
   Google Scholar
• World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Geneva: Author; 2006.
   Google Scholar
• Hingankar NK, Thorat SR, Deshpande A, et al. Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. Clin Infect Dis. 2012;54\(suppl 4):S348–S354.
   PubMed Web of Science ®Google Scholar
• Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: What is to be done? Occup Environ Med. 1998;55(4):272–277.
   Google Scholar
• Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19)1 690–1691.
   Web of Science ®Google Scholar
• Chaiwarith R, Wachirakaphan C, Kotarathititum W, Praparatanaphan J, Sirisanthana T, Supparatpinyo K. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis. 2007;11:413–416.
   PubMed Web of Science ®Google Scholar
• Mee P, Fielding K, Charalambous S, Churchyard G, Grant A. Evaluation of the WHO criteria for antiretroviral treat-ment failure among adults in South Africa. AIDS. 2008;22: 1971–1977.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-in-fected adults and adolescents. http://www.aidsinfo.nih.gov/contentfiles/Ivguidelines/adultandadolescentgl.pdf.
   Google Scholar
• Gazzard BG, on behalf of the BHIVA Treatment Guide-lines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;(9):563–608.
   Web of Science ®Google Scholar
• Kantor R, Diero L, DeLong A, et al. Misclassification of first-line antiretroviral treatment failure based on immu-nological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009;49(3):454–462.
   PubMed Web of Science ®Google Scholar
• National Committee for AIDS, Drugs and Prostitution Prevention and Control. Viet Nam AIDS Respomse: Progress Report 2012. Following up the 2011 Political Declaration on HIV/AIDS: Reporting period January 2010- December 2011. Hanoi; March 2012.
   Google Scholar
• Vidya M, Saravanan S, Uma S, et al. Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. Antivir Ther 2009;14(7)1 005–1009.
   Web of Science ®Google Scholar
• Zolfo M, Schapiro JM, Phan V, et al. Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. AIDS Res Hum Retroviruses. 2010;27(7):727–735.
   PubMed Web of Science ®Google Scholar
• Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010;18(5):156–163.
   PubMedGoogle Scholar
• Bartlett JA, Ribaudo HJ, Wallis CL, et al. Lopinavir/ ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012;26(11):1345–1354.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17(13): 1925–1932.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Hogg RS, Dong WWY, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191(3):339–347.
   PubMed Web of Science ®Google Scholar
• Wensing AMJ, Boucher CAB. Worldwide transmission of drug-resistant HIV. AIDS Rev. 2003;5(3):140–155.
   PubMedGoogle Scholar
• Taylor S, Allen S, Fidler S, et al. Stop study: after discon-tinuation of efavirenz, plasma concentrations may persist for 2 weeks or longer. Paper presented at the 11th Confer-ence on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA.
   Google Scholar
• Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65–72.
   PubMedGoogle Scholar
• Lee PK, Kieffer TL, Siliciano RF, Nettles RE. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 2006;57(5):803–805.
   PubMed Web of Science ®Google Scholar
• Verhofstede C, Van Wanzeele F, Van Der Gucht B, et al. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml. J Med ViroL 2007;79(9)1254–1260.
   Web of Science ®Google Scholar
• Mohey R, Jorgensen LB, Moller BK, Black FT, Kjems J, Obel N. Detection and quantification of proviral HIV-1 184MN in circulating CD4+ T cells of patients on HAART with a viremia less than 1000 copies/ml. J Clin Virol. 2005;34(4):257–267.
   PubMed Web of Science ®Google Scholar
• Cohen C. Low-level viremia in HIV-1 infection: conse-quences and implications for switching to a new regimen. HIV Clin Trials. 2009;10(2):116–124.
   PubMed Web of Science ®Google Scholar